With cardiovascular diseases forecasted to be the most common cause of premature death worldwide within the next decade, according to the World Health Organization (WHO), we committed ourselves to renewed efforts in this therapeutic area by moving our cardiovascular research to Ridgefield a few years ago.
 Boehringer Ingelheim has been at the forefront of research and development in the cardiovascular disease area for decades, establishing its market presence in the treatment of thromboembolic diseases as well as hypertension and consequential diseases. Ongoing research efforts in the thromboembolic area could be successfully completed by advancing a new product into preclinical development. We will continue to develop our cardio- vascular research platform in the area of atherothrombosis and widen our research to include heart failure.
To address the ever-increasing unmet medical need for treating these cardiovascular diseases, our Ridgefield scientists are already focusing on innovative approaches to identify novel and effective drugs that reach beyond current treatment regimes.
These programmes will benefit from close interaction with research scientists in our other drug discovery units. Targeting related human diseases, such as metabolic and immunological/ inflammatory disorders, will undoubtedly increase the opportunities for developing novel, innovative therapeutic agents in the fight against cardiovascular disease.
|
|
|
